Skip to content
Menu
Home
Science
Changing the Narrative
BXQ-350 MOA
mCRC
CIPN
Pediatrics
Pipeline
Clinical Trials
About Bexion
Executive Team
Board of Directors
Key Milestones
Advocacy Partners
Media & Press
Press Releases
Resources
Video Library
Abstracts
Posters
Case Studies
Investors & Partners
Corporate Profile
Events
Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial
Your browser does not support the video tag
Other Videos
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Immunostimulating Properties of BXQ-350
Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial
Comprehensive Investor Presentation
Bexion Pharmaceuticals Corporate Video
Bexion Highlight Reel
Alpha Summit Presentation
3rd Annual Glioblastoma Drug Development Presentation
Advancements TV Series presentation
UCSF Awards Video
Dr. Rixe Video – BXQ-350 MOA
Page load link
Go to Top
